Emerging immunotargets in bladder cancer

Francesco Massari, Chiara Ciccarese, Nuno Vau, Matteo Santoni, Rodolfo Montironi, Liang Cheng, Rita C. Marques, Marina Scarpelli, Jorge Fonseca, Marc R. Matrana, Moch Holger, Stefano Cascinu, Giampaolo Tortora, Antonio Lopez-Beltran

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Bladder cancer treatment, namely systemic therapy, was dominated in the last three decades due to the absence of newer therapeutic options other than chemotherapy regimens. Chemotherapy, by itself, both in first and second-line seems to have achieved the modest plateau of its possibilities at the cost of non-negligible toxicity. Targeted therapies, which changed the therapy of many different tumors, seem rather ineffective in bladder cancer. More recently, a new generation of Immunotherapy based regimens represent the most promising avenue for the future systemic treatment of bladder cancer. Checkpoint inhibition, namely PD1/PD-L1 pathway inhibition, showed impressive results in many other tumor types and are expected to become a major player in the treatment of bladder cancer. Other immunotherapy strategies such as fusion proteins represent distant, although promising, options. A brief overview of the current status of bladder cancer immunotherapy is presented.

Original languageEnglish (US)
Pages (from-to)757-770
Number of pages14
JournalCurrent Drug Targets
Volume17
Issue number7
StatePublished - Jun 1 2016

Fingerprint

Chemotherapy
Urinary Bladder Neoplasms
Tumors
Oncology
Toxicity
Immunotherapy
Fusion reactions
Therapeutics
Proteins
Drug Therapy
Neoplasms

Keywords

  • Bladder cancer
  • Clinical trials
  • Immunotherapy
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Massari, F., Ciccarese, C., Vau, N., Santoni, M., Montironi, R., Cheng, L., ... Lopez-Beltran, A. (2016). Emerging immunotargets in bladder cancer. Current Drug Targets, 17(7), 757-770.

Emerging immunotargets in bladder cancer. / Massari, Francesco; Ciccarese, Chiara; Vau, Nuno; Santoni, Matteo; Montironi, Rodolfo; Cheng, Liang; Marques, Rita C.; Scarpelli, Marina; Fonseca, Jorge; Matrana, Marc R.; Holger, Moch; Cascinu, Stefano; Tortora, Giampaolo; Lopez-Beltran, Antonio.

In: Current Drug Targets, Vol. 17, No. 7, 01.06.2016, p. 757-770.

Research output: Contribution to journalArticle

Massari, F, Ciccarese, C, Vau, N, Santoni, M, Montironi, R, Cheng, L, Marques, RC, Scarpelli, M, Fonseca, J, Matrana, MR, Holger, M, Cascinu, S, Tortora, G & Lopez-Beltran, A 2016, 'Emerging immunotargets in bladder cancer', Current Drug Targets, vol. 17, no. 7, pp. 757-770.
Massari F, Ciccarese C, Vau N, Santoni M, Montironi R, Cheng L et al. Emerging immunotargets in bladder cancer. Current Drug Targets. 2016 Jun 1;17(7):757-770.
Massari, Francesco ; Ciccarese, Chiara ; Vau, Nuno ; Santoni, Matteo ; Montironi, Rodolfo ; Cheng, Liang ; Marques, Rita C. ; Scarpelli, Marina ; Fonseca, Jorge ; Matrana, Marc R. ; Holger, Moch ; Cascinu, Stefano ; Tortora, Giampaolo ; Lopez-Beltran, Antonio. / Emerging immunotargets in bladder cancer. In: Current Drug Targets. 2016 ; Vol. 17, No. 7. pp. 757-770.
@article{4b47ec57bc1b41ecb3cc48dfc839b5bc,
title = "Emerging immunotargets in bladder cancer",
abstract = "Bladder cancer treatment, namely systemic therapy, was dominated in the last three decades due to the absence of newer therapeutic options other than chemotherapy regimens. Chemotherapy, by itself, both in first and second-line seems to have achieved the modest plateau of its possibilities at the cost of non-negligible toxicity. Targeted therapies, which changed the therapy of many different tumors, seem rather ineffective in bladder cancer. More recently, a new generation of Immunotherapy based regimens represent the most promising avenue for the future systemic treatment of bladder cancer. Checkpoint inhibition, namely PD1/PD-L1 pathway inhibition, showed impressive results in many other tumor types and are expected to become a major player in the treatment of bladder cancer. Other immunotherapy strategies such as fusion proteins represent distant, although promising, options. A brief overview of the current status of bladder cancer immunotherapy is presented.",
keywords = "Bladder cancer, Clinical trials, Immunotherapy, Urothelial carcinoma",
author = "Francesco Massari and Chiara Ciccarese and Nuno Vau and Matteo Santoni and Rodolfo Montironi and Liang Cheng and Marques, {Rita C.} and Marina Scarpelli and Jorge Fonseca and Matrana, {Marc R.} and Moch Holger and Stefano Cascinu and Giampaolo Tortora and Antonio Lopez-Beltran",
year = "2016",
month = "6",
day = "1",
language = "English (US)",
volume = "17",
pages = "757--770",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Emerging immunotargets in bladder cancer

AU - Massari, Francesco

AU - Ciccarese, Chiara

AU - Vau, Nuno

AU - Santoni, Matteo

AU - Montironi, Rodolfo

AU - Cheng, Liang

AU - Marques, Rita C.

AU - Scarpelli, Marina

AU - Fonseca, Jorge

AU - Matrana, Marc R.

AU - Holger, Moch

AU - Cascinu, Stefano

AU - Tortora, Giampaolo

AU - Lopez-Beltran, Antonio

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Bladder cancer treatment, namely systemic therapy, was dominated in the last three decades due to the absence of newer therapeutic options other than chemotherapy regimens. Chemotherapy, by itself, both in first and second-line seems to have achieved the modest plateau of its possibilities at the cost of non-negligible toxicity. Targeted therapies, which changed the therapy of many different tumors, seem rather ineffective in bladder cancer. More recently, a new generation of Immunotherapy based regimens represent the most promising avenue for the future systemic treatment of bladder cancer. Checkpoint inhibition, namely PD1/PD-L1 pathway inhibition, showed impressive results in many other tumor types and are expected to become a major player in the treatment of bladder cancer. Other immunotherapy strategies such as fusion proteins represent distant, although promising, options. A brief overview of the current status of bladder cancer immunotherapy is presented.

AB - Bladder cancer treatment, namely systemic therapy, was dominated in the last three decades due to the absence of newer therapeutic options other than chemotherapy regimens. Chemotherapy, by itself, both in first and second-line seems to have achieved the modest plateau of its possibilities at the cost of non-negligible toxicity. Targeted therapies, which changed the therapy of many different tumors, seem rather ineffective in bladder cancer. More recently, a new generation of Immunotherapy based regimens represent the most promising avenue for the future systemic treatment of bladder cancer. Checkpoint inhibition, namely PD1/PD-L1 pathway inhibition, showed impressive results in many other tumor types and are expected to become a major player in the treatment of bladder cancer. Other immunotherapy strategies such as fusion proteins represent distant, although promising, options. A brief overview of the current status of bladder cancer immunotherapy is presented.

KW - Bladder cancer

KW - Clinical trials

KW - Immunotherapy

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84964203015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964203015&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 757

EP - 770

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 7

ER -